Clinical Trial Update: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus [Phase 4]

View source ↗

Summary

Phase 4 long-term safety study of canagliflozin (TA-7284) in combination with insulin for type 2 diabetes mellitus has completed, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)
• Insulin (insulin)

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2019-03-14